Cardiogen
Not FDA approvedSynthetic short bioregulator peptide
Very thin human evidence
- Regulatory standing. Sold as a research chemical, not approved
- Animal / preclinical only. Evidence is largely animal or in-vitro
- No registered human trials. Nothing registered on ClinicalTrials.gov
- No sources. Nothing cited to verify
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Cardiogen is described in the research literature as a short synthetic peptide, usually reported as the tetrapeptide Ala-Glu-Asp-Arg, from the Russian peptide bioregulator research program. It is proposed to act on gene expression in heart and connective tissue cells, but this mechanism is not well established. The chemical formula listed in the gathered database record (C7H15NO3, 161.2 g/mol) does not match a four amino acid peptide, so the database identity for this entry is unclear.
What the evidence shows
Most published work consists of cell and animal studies, largely from one research group. There is only one registered human trial with no reported phase, and no benefit in humans has been established.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.